英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

unwilling    音标拼音: [ənw'ɪlɪŋ]
a. 不愿意的,勉强的

不愿意的,勉强的

unwilling
adj 1: not disposed or inclined toward; "an unwilling
assistant"; "unwilling to face facts" [ant: {willing}]
2: in spite of contrary volition

Unwilling \Un*will"ing\, a.
Not willing; loath; disinclined; reluctant; as, an unwilling
servant.
[1913 Webster]

And drop at last, but in unwilling ears,
This saving counsel, "Keep your piece nine years."
--Pope.
[1913 Webster] -- {Un*will"ing*ly}, adv. --
{Un*will"ing*ness}, n.
[1913 Webster]


请选择你想看的字典辞典：
单词字典翻译
Unwilling查看　Unwilling　在百度字典中的解释百度英翻中〔查看〕
Unwilling查看　Unwilling　在Google字典中的解释Google英翻中〔查看〕
Unwilling查看　Unwilling　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated . . .
    We randomly assigned patients with untreated BRAF V600E–mutated metastatic colorectal cancer to receive EC, EC+mFOLFOX6, or standard care The two primary end points were objective response
  • BRAFV600E mutant metastatic colorectal cancer: Current . . .
    Abstract Detection of the BRAF V600E mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (mCRC), identifying a subgroup of patients who derive modest benefit from standard treatments and have extremely poor prognosis
  • Upfront Modified FOLFOXIRI Plus Panitumumab for RAS BRAF Wild . . .
    We report 5-year results of the phase III randomized TRIPLETE study Eligible patients with RAS BRAF wild-type metastatic colorectal cancer (mCRC) received first-line modified fluorouracil, leucovo
  • Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer
    Interview Summary Colorectal cancer (CRC) is the third most common cancer worldwide, and the second leading cause of cancer death Approximately one in five patients with CRC present with metastatic disease at diagnosis The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer (mCRC), and is characterised by an aggressive clinical course and poor prognosis This
  • BREAKWATER: Primary analysis of first-line (1L) encorafenib . . .
    BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC) If you have the appropriate software installed, you can download article citation data to the citation manager of your choice Simply select your manager software from the list below and click Download
  • U. S. FDA Grants Full Approval to Pfizer’s BRAFTOVI . . .
    BRAFTOVI ® (encorafenib) is indicated, in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-authorized test Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF CRC
  • Molecular profiling of BRAF-V600E-mutant metastatic . . . - Nature
    Prespecified exploratory genomic and transcriptomic profiling of tumor tissues and circulating tumor DNA from patients with BRAF-V600E-mutant metastatic colorectal cancer who participated in the
  • BREAKWATER at ASCO 2026: Encorafenib plus Cetuximab and . . .
    BREAKWATER at ASCO 2026: Encorafenib plus Cetuximab and FOLFIRI in BRAF V600E-Mutant mCRC At the 2026 ASCO Annual Meeting, Scott Kopetz presented results from BREAKWATER Cohort 3, evaluating first-line encorafenib plus cetuximab and FOLFIRI in patients with BRAF V600E-mutant metastatic colorectal cancer The study was presented as Abstract LBA3503
  • FDA Fully Approves Braftovi Combo for BRAF V600E Metastatic . . .
    The U S FDA has granted traditional approval to Braftovi with Erbitux and chemo for adults with BRAF V600E metastatic colorectal cancer
  • Encorafenib, cetuximab and chemotherapy in BRAF-mutant . . .
    Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study Historically, first-line treatment of BRAF





中文字典-英文字典  2005-2009